A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD1)
I4V-MC-JAHL - ClinicalTrials.gov - NCT03334396
The purpose of this study is to evaluate the efficacy and safety of baricitinib as a single drug treatment in participants with moderate to severe atopic dermatitis (eczema).
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Atopic DermatitisWhat the trial is testing?
BaricitinibCould I receive a Placebo?
YesEnrollment Goal
660Trial Dates
Nov 23, 2017 - Aug 16, 2019How long will I be in the trial?
Your participation could last up to 25 weeks and include up to 9 visits to the study center.Trial Phase
IIILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo